Insoluble drug delivery technologies: Review of health benefits and business potentials

Abstract

section 505(b)(2) 2. The majority of those NDA's under this section are new formulations. New dosage form, change of forms of drugs (Ester/salt), prodrug/active metabolite of drug and different route of administration are the few changes that the pharmaceutical companies are exploring for 505(b)(2) fillings 3. The insoluble drugs are being reformulated. Hence this review summarises various sol-ubilisation technologies and their commercial and health benefits. This review discusses drug formulations approved exploring different solu-bilisation technologies with insight to health benefits and commercial profits.